Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Clinical Research Institute of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Ethnopharmacol. 2015 Jan 15;159:84-92. doi: 10.1016/j.jep.2014.11.013. Epub 2014 Nov 18.
Shexiang Tongxin dropping pill (STDP) is a formulation of Traditional Chinese Medicine mainly used for clinical treatment of stable angina pectoris in China.
To investigate the effects and mechanisms of STDP treatment on atherosclerosis.
ApoE deficient (ApoE(-/-)) mice were utilized to evaluate the effect of STDP treatment (30 mg/kg/day) on atherosclerotic lesions. Histopathological features of atherosclerotic lesions, serum levels of lipid proteins, parameters of oxidative stress and pro-inflammatory cytokines were measured by H&E staining, Masson's trichrome staining and ELISA, respectively. Real-time PCR analyses were performed to examine the aortic expression of atherosclerosis-associated microRNAs.
The STDP treatment resulted in attenuated atherosclerotic lesion manifested by reduced lipid deposition, fibrosis and oxidative stress. It also led to increase in serum levels of GSH and SOD, decrease in MDA, decrease in CHO, TG, LDL, ox-LDL and increase in HDL, respectively. Additionally, the levels of pro-inflammatory cytokines including IL-2, IL-6, TNF-α and γ-IFN were markedly reduced by STDP treatment. Furthermore, STDP treatment was associated with a significant reduction in the aortic expression of miR-21a, miR-132, miR-126a, miR-155 and increased expression of miR-20a.
Our results demonstrated for the first time that STDP attenuated atherosclerotic lesions in ApoE(-/-) mouse model. Moreover, STDP treatment exhibited multi-targeting effects on pathological, biochemical and molecular aspects of atherosclerosis implicating lipid regulation, fibrosis, inflammation and oxidative stress. Findings from the current study warrant further evaluation of the clinical application of STDP in atherosclerosis treatment.
麝香通心滴丸（STDP）是一种中药制剂，主要用于中国临床治疗稳定性心绞痛。
研究 STDP 治疗对动脉粥样硬化的作用及其机制。
利用载脂蛋白 E 基因敲除（ApoE(-/-)) 小鼠评估 STDP 治疗（30mg/kg/天）对动脉粥样硬化病变的影响。通过 H&E 染色、马松三色染色和 ELISA 分别测量动脉粥样硬化病变的组织病理学特征、血脂蛋白水平、氧化应激和促炎细胞因子参数。实时 PCR 分析用于检查与动脉粥样硬化相关的 microRNA 在主动脉中的表达。
STDP 治疗导致动脉粥样硬化病变减轻，表现为脂质沉积、纤维化和氧化应激减少。它还导致血清 GSH 和 SOD 水平升高，MDA 降低，CHO、TG、LDL、ox-LDL 降低，HDL 升高。此外，STDP 治疗还显著降低了促炎细胞因子 IL-2、IL-6、TNF-α 和 γ-IFN 的水平。此外，STDP 治疗与 miR-21a、miR-132、miR-126a、miR-155 在主动脉中的表达显著降低和 miR-20a 的表达增加有关。
我们的研究结果首次表明，STDP 可减轻 ApoE(-/-) 小鼠模型中的动脉粥样硬化病变。此外，STDP 治疗在动脉粥样硬化的病理、生化和分子方面表现出多靶点作用，涉及脂质调节、纤维化、炎症和氧化应激。本研究的结果值得进一步评估 STDP 在动脉粥样硬化治疗中的临床应用。
